Because rapamycin has broad anti-proliferative activity across a series of NSCLC cell lines, we hypothesized that combining rapamycin with pemetrexed might enhance mTOR inhibition, suppress TS expression, and synergistically decrease proliferation of NSCLC cells. Here, TYMS is linked to non-small cell lung carcinoma.